Air Canada Reports Third Quarter 2024 Financial Results

  • Third quarter operating revenues of $6.1 billion decreased 4% year over year.
  • Third quarter operating income of $1.040 billion and adjusted EBITDA* of $1.523 billion decreased $375 million and $307 million year over year, respectively.
  • Generated cash flows from operating activities of $737 million and free cash flow* of $282 million in the quarter, a year-over-year increase of $329 million and $147 million, respectively.
  • Leverage ratio* of 1.0 as at September 30, 2024, compared to 1.1 at end of 2023.
  • Normal course issuer bid announced.

MONTREAL, Nov. 1, 2024 /PRNewswire/ – Air Canada today reported its third quarter 2024 financial results.

“Air Canada reported solid results for the third quarter on key metrics, with operating revenues of $6.1 billion and operating income of $1 billion. Adjusted EBITDA of $1.5 billion and our adjusted earnings per share of $2.57 were both ahead of market expectations. We delivered on our ongoing operational improvement program, with quarterly on-time performance rising eight percentage points over the same period in 2023. I thank all our employees for their care and dedication in safely moving nearly 13 million customers in the quarter, including our Olympic and Paralympic athletes to the summer games in Paris,” said Michael Rousseau, President and Chief Executive of Air Canada.

“Summer is our peak season and this year our pilot contract negotiations added complexity. We proactively offered options and flexibility to customers, and I am proud that we concluded a mutually beneficial agreement without significant disruption to customers and with a contained revenue impact. I thank our customers for their loyalty and reiterate our promise to keep providing industry-leading products and services to them.

“The demand environment remains favourable. We have adjusted our full year guidance and underlying assumptions to account for the evolution of the fuel price environment and for certain contract-related adjustments. We are delivering on our commitments and are confident in our future. We are now announcing a new share buyback program, addressing some of the dilution experienced from financing decisions necessary during the pandemic, and returning value to shareholders. This additional step, after paying down our debt and funding our growth, is consistent with our capital allocation roadmap and our strategic plan, which we will detail at our Investor Day on December 17, 2024,” said Mr. Rousseau.

*Adjusted CASM, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), adjusted EBITDA margin, leverage ratio, net debt, adjusted pre-tax income (loss), adjusted net income (loss), adjusted earnings (loss) per share, and free cash flow are referred to in this news release. Such measures are non-GAAP financial measures, non-GAAP ratios, or supplementary financial measures, are not recognized measures for financial statement presentation under GAAP, do not have standardized meanings, may not be comparable to similar measures presented by other entities and should not be considered a substitute for or superior to GAAP results. Refer to the “Non-GAAP Financial Measures” section of this news release for descriptions of these measures, and for a reconciliation of Air Canada non-GAAP measures used in this news release to the most comparable GAAP financial measure.

Third Quarter 2024 Financial Results

The following is an overview of Air Canada’s results of operations and financial position for the third quarter 2024 compared to the third quarter 2023.

  • Operating revenues of $6.106 billion decreased $238 million or 4%, resulting from lower passenger revenues.
  • Operated capacity increased 3%, lower than the capacity guidance of 4%-4.5% increase communicated in Air Canada’s news release dated August 7, 2024. This was primarily due to fleet constraints and to adjustments made to the operating schedule.
  • Operating expenses of $5.066 billion increased $137 million or 3%. The increase was largely due to higher costs in most line items due to capacity growth and was partially offset by certain contract-related adjustments recorded this quarter.
  • Operating income of $1.040 billion, with an operating margin of 17.0%, declined $375 million.
  • Adjusted EBITDA of $1.523 billion, with an adjusted EBITDA margin* of 24.9%, declined $307 million.
  • Net income of $2.035 billion, which included a favourable tax asset recognition of $1.154 billion, and diluted earnings per share of $5.38 compared to $1.250 billion and $3.08 per diluted share, respectively.
  • Adjusted net income* of $969 million and adjusted earnings per diluted share* of $2.57, compared to $1.281 billion and $3.41 per diluted share, respectively.
  • Adjusted CASM* of 12.15 cents decreased 0.4%, primarily due to the impact of contract-related adjustments recorded in the third quarter of 2024.
  • Net cash flows from operating activities of $737 million increased $329 million.
  • Free cash flow* of $282 million increased $147 million.
  • Net debt-to-adjusted EBITDA ratio* (leverage ratio) was 1.0 at September 30, 2024, compared to 1.1 at December 31, 2023.

Outlook

For the full year 2024, Air Canada is updating its guidance to account for updated expectations of jet fuel prices and the impact of contract-related cost adjustments. Full year 2024 guidance is as follows:

Metric

2024 Guidance

Prior 2024 Guidance

ASM capacity

Approximately 5% increase versus 2023

5.5% to 6.5% increase versus 2023

Adjusted CASM

Approximately 2% increase versus 2023

2.5% to 3.5% increase versus 2023

Adjusted EBITDA

Approximately $3.5 billion

$3.1 billion to $3.4 billion

Major Assumptions

Air Canada made assumptions in providing its guidance—including moderate Canadian GDP growth for 2024. Air Canada also assumes that the Canadian dollar will trade, on average, at C$1.36 per U.S. dollar for the full year 2024 and that the price of jet fuel will average C$1.00 per litre for the full year 2024.

Normal Course Issuer Bid

Air Canada is also announcing today that the Toronto Stock Exchange (“TSX”) has accepted notice of its intention to make a normal course issuer bid (“NCIB”) allowing it to purchase for cancellation up to 35,783,842 of its Class A variable voting shares and Class B voting shares (collectively the “Shares”) in accordance with the rules of the TSX.

Air Canada believes that purchases of Shares under the NCIB will allow it to address some of the shareholder dilution experienced from financing decisions necessary during the pandemic. Air Canada further believes that the market price of its Shares from time to time may not fully reflect the underlying value of its business and future business prospects. In such circumstances, the purchase of Shares under the NCIB may be an attractive and appropriate use of its available cash, consistent with Air Canada’s priority of investing in its growth, maintaining balance sheet strength and generating shareholder value through a balanced capital allocation strategy.

Air Canada is authorized by the TSX to purchase up to 35,783,842 Shares under the NCIB, being about 10% of the public float of its Shares. As at October 22, 2024, the number of outstanding Shares totalled 358,493,006, of which 357,838,424 Shares represented the public float. Purchases under the NCIB are authorized during the period from November 5, 2024 to November 4, 2025. Decisions regarding the amount and timing of purchases of Shares will be based on market conditions, share price and other factors. Air Canada may elect to modify, suspend or discontinue the NCIB at any time.

Purchases will be made through open market transactions on the TSX or Canadian alternative trading systems, if eligible, or such other means as securities regulatory authorities may allow, including block purchases, pre-arranged crosses or exempt offers, as well as private agreements under an issuer bid exemption order issued by a securities regulatory authority. Air Canada will pay the market price at the time of acquisition for any Share purchased, plus brokerage fees, or such other price as may be allowed. Any purchases made under an issuer bid exemption order would be at a discount to the prevailing market price of the Shares or otherwise in accordance with the terms of the order. 

Within the past 12 months, Air Canada has not purchased any of its Shares. The average daily trading volume (“ADTV”) of the Shares on the TSX was 2,143,460 Shares for the six-month period ended September 30, 2024. Under TSX rules, Air Canada may accordingly purchase up to 535,865 Shares on the TSX on any trading day, being 25% of the ADTV. Air Canada may also, once weekly, purchase a block of Shares not directly or indirectly owned by insiders, which may exceed such daily limit, in accordance with TSX rules. All Shares purchased pursuant to the NCIB will be cancelled.

Air Canada will enter into an automatic share purchase plan (the “Plan”) with its designated broker to be effective on the commencement date of the NCIB. The Plan will allow for the purchase of Shares at times when Air Canada would ordinarily not be active in the market due to regulatory restrictions, self-imposed blackout periods or otherwise. Purchases by the designated broker made under the Plan, if any, will be based on parameters established by Air Canada in accordance with the rules of the TSX, applicable securities laws and the terms of the Plan. Shares may in Air Canada’s discretion be purchased under the NCIB outside of the self-imposed black-out or other restricted periods in compliance with the rules of the TSX and applicable securities laws.

Non-GAAP Financial Measures

Below is a description of certain non-GAAP financial measures and ratios used by Air Canada to provide readers with additional information on its financial and operating performance. Such measures are not recognized measures for financial statement presentation under GAAP, do not have standardized meanings, may not be comparable to similar measures presented by other entities and should not be considered a substitute for or superior to GAAP results. The non-GAAP financial measures or ratios described in this section typically have exclusions or adjustments that include one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded because the company believes these may distort the analysis of certain business trends and render comparative analysis across periods less meaningful and their exclusion generally allows for a more meaningful analysis of Air Canada’s operating expense performance and may allow for a more meaningful comparison to other airlines.

Air Canada excludes the effect of impairment of assets, if any, when calculating adjusted CASM, adjusted EBITDA, adjusted EBITDA margin, adjusted pre-tax income (loss) and adjusted net income (loss) as it may distort the analysis of certain business trends and render comparative analysis across periods or to other airlines less meaningful. Air Canada did not record charges for impairment of assets in the first nine months of 2024 or in 2023.

A charge of $34 million was recorded in the third quarter of 2024 in other operating expenses related to estimated costs associated with contractual lease obligations. Air Canada excluded this non-recurring expense in computing adjusted CASM, adjusted EBITDA, adjusted pre-tax income and adjusted net income.

Adjusted CASM

Air Canada uses adjusted CASM to assess the operating and cost performance of its ongoing airline business without the effects of aircraft fuel expense, the cost of ground packages at Air Canada Vacations and freighter costs as these items may distort the analysis of certain business trends and render comparative analysis across periods less meaningful and their exclusion generally allows for a more meaningful analysis of Air Canada’s operating expense performance and may allow for a more meaningful comparison to that of other airlines.

In calculating adjusted CASM, aircraft fuel expense is excluded from operating expense results as it fluctuates widely depending on many factors, including international market conditions, geopolitical events, jet fuel refining costs and Canada/U.S. currency exchange rates. Air Canada also incurs expenses related to ground packages at Air Canada Vacations which some airlines, without comparable tour operator businesses, may not incur. In addition, these costs do not generate ASMs and therefore excluding these costs from operating expense results provides for a more meaningful comparison across periods when such costs may vary.

Air Canada also incurs expenses related to the operation of freighter aircraft which some airlines, without comparable cargo businesses, may not incur. Air Canada had six Boeing 767 dedicated freighter aircraft in service as at September 30, 2024, and six as at September 30, 2023. These costs do not generate ASMs and therefore excluding these costs from operating expense results provides for a more meaningful comparison of the passenger airline business across periods.

Adjusted CASM is reconciled to GAAP operating expense as follows:

(Canadian dollars in millions, except where indicated)

Third Quarter

First Nine Months

2024

2023

Change

2024

2023

Change

Operating expense – GAAP

$

5,066

$

4,929

$

137

$

15,334

$

14,458

$

876

Adjusted for:













Aircraft fuel


(1,377)


(1,365)


(12)


(3,964)


(3,927)


(37)

Ground package costs


(102)


(99)


(3)


(574)


(543)


(31)

Freighter costs (excluding fuel)


(40)


(41)


1


(113)


(111)


(2)

Provision for contractual lease obligations


(34)



(34)


(34)



(34)

Operating expense, adjusted for the above-noted items

$

3,513

$

3,424

$

89


10,649


9,877


772

ASMs (millions)


28,892


28,060


3.0 %


79,432


74,573


6.5 %

Adjusted CASM (cents)

¢

12.15

¢

12.20

¢

(0.05)

¢

13.41

¢

13.24

¢

0.17

EBITDA and Adjusted EBITDA

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) is commonly used in the airline industry and is used by Air Canada as a means to view operating results before interest, taxes, depreciation and amortization as these costs can vary significantly among airlines due to differences in the way airlines finance their aircraft and other assets.

Adjusted EBITDA margin (adjusted EBITDA as a percentage of operating revenues) is commonly used in the airline industry and is used by Air Canada as a means to measure the operating margin before interest, taxes, depreciation and amortization as these costs can vary significantly among airlines due to differences in the way airlines finance their aircraft and other assets.

Adjusted EBITDA and adjusted EBITDA margin are reconciled to GAAP operating income (loss) as follows:


Third Quarter

First Nine Months

(Canadian dollars in millions, except where indicated)

2024

2023

Change

2024

2023

Change

Operating income – GAAP

$

1,040

$

1,415

$

(375)

$

1,517

$

2,200

$

(683)

Add back:













Depreciation and amortization


449


415


34


1,339


1,261


78

EBITDA


1,489


1,830


(341)


2,856


3,461


(605)

Add back:













Provision for contractual lease obligations


34



34


34



34

Adjusted EBITDA

$

1,523

$

1,830

$

(307)

$

2,890

$

3,461

$

(571)

Operating revenues

$

6,106

$

6,344

$

(238)

$

16,851

$

16,658

$

193

Operating margin (%)


17.0


22.3


(5.3) pp


9.0


13.2


(4.2) pp

Adjusted EBITDA margin (%)


24.9


28.8


(3.9) pp


17.2


20.8


(3.6) pp

Adjusted Pre-tax Income (Loss)

Adjusted pre-tax income (loss) is used by Air Canada to assess the overall pre-tax financial performance of its business without the effects of foreign exchange gains or losses, net interest relating to employee benefits, gains or losses on financial instruments recorded at fair value, gains or losses on sale and leaseback of assets, gains or losses on disposal of assets, gains or losses on debt settlements and modifications, as these items may distort the analysis of certain business trends and render comparative analysis across periods or to other airlines less meaningful.

Adjusted pre-tax income (loss) is reconciled to GAAP income (loss) before income taxes as follows:

(Canadian dollars in millions)

Third Quarter

First Nine Months

2024

2023

$ Change

2024

2023

$ Change

Income before income taxes – GAAP

$

897

$

1,317

$

(420)

$

1,236

$

2,090

$

(854)

Adjusted for:













Provision for contractual lease obligations


34



34


34



34

Foreign exchange (gain) loss


85


61


24


28


(317)


345

Net interest relating to employee benefits


(5)


(6)


1


(16)


(18)


2

Gain on financial instruments recorded at fair value


(26)


(101)


75


(66)


(24)


(42)

Loss on debt settlement



7


(7)


46


9


37

Adjusted pre-tax income

$

985

$

1,278

$

(293)

$

1,262

$

1,740

$

(478)

Adjusted Net Income (Loss) and Adjusted Earnings (Loss) Per Share – Diluted

Air Canada uses adjusted net income (loss) and adjusted earnings (loss) per share – diluted as a means to assess the overall financial performance of its business without the after-tax effects of foreign exchange gains or losses, net financing expense relating to employee benefits, gains or losses on financial instruments recorded at fair value, gains or losses on sale and leaseback of assets, gains or losses on debt settlements and modifications, gains or losses on disposal of assets as these items may distort the analysis of certain business trends and render comparative analysis to other airlines less meaningful.

Adjusted net income (loss) and adjusted earnings (loss) per share are reconciled to GAAP net income as follows:

(Canadian dollars in millions)

Third Quarter

First Nine Months

2024

2023

$ Change

2024

2023

$ Change

Net income – GAAP

$

2,035

$

1,250

$

785

$

2,364

$

2,092

$

272

Adjusted for:













Provision for contractual lease obligations


34



34


34



34

Foreign exchange (gain) loss


85


61


24


28


(317)


345

Net interest relating to employee benefits


(5)


(6)


1


(16)


(18)


2

Gain on financial instruments recorded at fair value


(26)


(101)


75


(66)


(24)


(42)

Loss on debt settlement



7


(7)


46


9


37

Income tax, including for the above reconciling items (1) 


(1,154)


70


(1,224)


(1,148)


15


(1,163)

Adjusted net income  

$

969

$

1,281

$

(312)

$

1,242

$

1,757

$

(515)

Weighted average number of outstanding shares used in computing diluted income per share (in millions)


376


376



376


376


Adjusted earnings per share – diluted 

$

2.57

$

3.41

$

(0.84)

$

3.30

$

4.67

$

(1.37)





(1)

In the third quarter of 2024, previously unrecognized deferred income tax asset was recognized which included a deferred income tax recovery of $1,154 million recorded in the consolidated statement of operations.  This deferred income tax recovery of $1,154 million is removed from the adjusted net income.  In 2023, the deferred income tax recovery recorded in other comprehensive income related to remeasurements on employee benefit liabilities was offset by a deferred income tax expense that was recorded through Air Canada’s consolidated statement of operations. This expense was removed from adjusted net income. 

The table below reflects the share amounts used in the computation of basic and diluted earnings per share on an adjusted earnings per share basis:

(In millions)

Third Quarter

First Nine Months

2024

2023

2024

2023

Weighted average number of shares outstanding – basic

358

358

358

358

Effect of dilution

18

18

18

18

Weighted average number of shares outstanding – diluted

376

376

376

376

Free Cash Flow

Air Canada uses free cash flow as an indicator of the financial strength and performance of its business, indicating the amount of cash Air Canada can generate from operations and after capital expenditures. Free cash flow is calculated as net cash flows from operating activities minus additions to property, equipment, and intangible assets, and is net of proceeds from sale and leaseback transactions.

The table below reconciles free cash flow to net cash flows from (used in) operating activities for the periods indicated.


Third Quarter

First Nine Months

(Canadian dollars in millions)

2024

2023

$ Change

2024

2023

$ Change

Net cash flows from operating activities 

$

737

$

408

$

329

$

3,253

$

3,335

$

(82)

Additions to property, equipment, and intangible assets 


(455)


(273)


(182)


(1,464)


(1,248)


(216)

Free cash flow 

$

282

$

135

$

147

$

1,789

$

2,087

$

(298)

Net Debt

Net debt is a capital management measure and a key component of the capital managed by Air Canada and provides management with a measure of its net indebtedness.

Net Debt to Trailing 12-Month Adjusted EBITDA (Leverage Ratio)

Net debt to trailing 12-month adjusted EBITDA ratio (also referred to as “leverage ratio”) is commonly used in the airline industry and is used by Air Canada as a means to measure financial leverage. Leverage ratio is calculated by dividing net debt by trailing 12-month adjusted EBITDA.

The table below reconciles leverage ratio to Air Canada’s net debt balances as at the dates indicated.

(Canadian dollars in millions)

September 30, 2024

December 31, 2023

Change

Total long-term debt and lease liabilities

$

10,716

$

12,996

$

(2,280)

Current portion of long-term debt and lease liabilities


1,652


866


786

Total long-term debt and lease liabilities (including current portion)


12,368


13,862


(1,494)

Less cash, cash equivalents and short- and long-term investments


(8,942)


(9,295)


353

Net debt (1)

$

3,426

$

4,567

$

(1,141)

Adjusted EBITDA (trailing 12 months)

$

3,411


3,982


(571)

Net debt to adjusted EBITDA ratio


1.0


1.1


(0.1)

For further information on Air Canada’s public disclosure file, including Air Canada’s 2023 Annual Information Form, dated March 4, 2024, consult SEDAR at www.sedarplus.ca.

Third Quarter 2024 Conference Call

Air Canada will host its quarterly analysts’ call today, Friday, November 1, 2024, at 8:00 a.m. ET. Michael Rousseau, President and Chief Executive Officer, John Di Bert, Executive Vice President and Chief Financial Officer, and Mark Galardo, Executive Vice President, Revenue and Network Planning and President, Cargo, will present the results and be available for analysts’ questions. Immediately following the analysts’ Q&A session, Mr. Di Bert and Pierre Houle, Vice President and Treasurer, will be available to answer questions from term loan B lenders and holders of Air Canada bonds.

Media and the public may access this call on a listen-in basis. Details are as follows:

CAUTION REGARDING FORWARD-LOOKING INFORMATION

This news release includes forward-looking statements within the meaning of applicable securities laws. Forward-looking statements relate to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable. These statements may involve, but are not limited to, comments relating to guidance, strategies, expectations, planned operations or future actions. Forward-looking statements are identified using terms and phrases such as “preliminary”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will”, “would”, and similar terms and phrases, including references to assumptions.

Forward-looking statements, by their nature, are based on assumptions including those described herein and are subject to important risks and uncertainties. Forward-looking statements cannot be relied upon due to, among other things, changing external events and general uncertainties of the business of Air Canada. Actual results may differ materially from results indicated in forward-looking statements due to a number of factors, including those discussed below.

Factors that may cause results to differ materially from results indicated in forward-looking statements include economic conditions as well as geopolitical conditions such as the military conflicts in the Middle East and between Russia and Ukraine, Air Canada’s ability to successfully achieve or sustain positive net profitability, industry and market conditions and the demand environment, competition, Air Canada’s dependence on technology, cybersecurity risks, interruptions of service, climate change and environmental factors (including weather systems and other natural phenomena and factors arising from anthropogenic sources), Air Canada’s dependence on key suppliers (including government agencies and other stakeholders supporting airport and airline operations), employee and labour relations and costs, Air Canada’s ability to successfully implement appropriate strategic and other important initiatives (including Air Canada’s ability to manage operating costs), energy prices, Air Canada’s ability to pay its indebtedness and maintain or increase liquidity, Air Canada’s dependence on regional and other carriers, Air Canada’s ability to attract and retain required personnel, epidemic diseases, changes in laws, regulatory developments or proceedings, terrorist acts, war, Air Canada’s ability to successfully operate its loyalty program, casualty losses, Air Canada’s dependence on Star Alliance® and joint ventures, Air Canada’s ability to preserve and grow its brand, pending and future litigation and actions by third parties, currency exchange fluctuations, limitations due to restrictive covenants, insurance issues and costs, and pension plan obligations as well as the factors identified in Air Canada’s public disclosure file available at www.sedarplus.ca and, in particular, those identified in section 18 “Risk Factors” of Air Canada’s 2023 MD&A and in section 14 “Risk Factors” of Air Canada’s Third Quarter 2024 MD&A.

Air Canada has and continues to establish targets, make commitments and assess the impact regarding climate change, and related initiatives, plans and proposals that Air Canada and other stakeholders (including government, regulatory and other bodies) are pursuing in relation to climate change and carbon emissions. The achievement of our commitments and targets depends on many factors, including the combined actions of governments, industry, suppliers and other stakeholders and actors, as well as the development and implementation of new technologies. In particular, our 2030 carbon emission-related targets and our related 2050 aspiration are ambitious and heavily dependent on new technologies, renewable energies and the availability of a sufficient supply of sustainable aviation fuels (SAF), which continues to present serious challenges. In addition, Air Canada has incurred, and expects to continue to incur, costs to achieve its goal of net-zero carbon emissions and to comply with environmental sustainability legislation and regulation and other standards and accords. The precise nature of future binding or non-binding legislation, regulation, standards and accords, on which local and international stakeholders are increasingly focusing, cannot be predicted with any degree of certainty, nor can their financial, operational or other impact. There can be no assurance of the extent to which any of our climate goals will be achieved or that any future investments that we make in furtherance of achieving our climate goals will produce the expected results or meet increasing stakeholder environmental, social and governance expectations. Moreover, future events could lead Air Canada to prioritize other nearer-term interests over progressing toward our current climate goals based on business strategy, economic, regulatory and social factors, and potential pressure from investors, activist groups or other stakeholders. If we are unable to meet or properly report on our progress toward achieving our climate change goals and commitments, we could face adverse publicity and reactions from investors, customers, advocacy groups or other stakeholders, which could result in reputational harm or other adverse effects to Air Canada.

The forward-looking statements contained or incorporated by reference in this news release represent Air Canada’s expectations as of the date of this news release (or as of the date they are otherwise stated to be made) and are subject to change after such date. However, Air Canada disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

About Air Canada

Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and Internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, where members can earn or redeem points on the world’s largest airline partner network of 45 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers more travel choices than any other Canadian tour operator to hundreds of destinations worldwide, with a wide selection of hotels, flights, cruises, day tours, and car rentals. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft.  Air Canada aims to achieve a long-term aspirational goal of net-zero GHG emissions by 2050. Air Canada shares are publicly traded on the TSX in Canada and the OTCQX in the US.

Internet:         aircanada.com/media

Read Our Annual Report Here

Sign up for Air Canada news: aircanada.com

Media Resources:

Photos
Videos
B-Roll
Articles

Selected Financial Metrics and Statistics

The financial and operating highlights for Air Canada for the periods indicated are as follows:

(Canadian dollars in millions, except per share data or where indicated)

Third Quarter

First Nine Months

Financial Performance Metrics

2024

2023

Change
$

2024

2023

Change
$

Operating revenues

6,106

6,344

(238)

16,851

16,658

193

Operating income

1,040

1,415

(375)

1,517

2,200

(683)

Operating margin (1) (%)

17.0

22.3

(5.3) pp (8)

9.0

13.2

(4.2) pp

Adjusted EBITDA (2)

1,523

1,830

(307)

2,890

3,461

(571)

Adjusted EBITDA margin (2) (%)

24.9

28.8

(3.9) pp

17.2

20.8

(3.6) pp

Income before income taxes

897

1,317

(420)

1,236

2,090

(854)

Net income

2,035

1,250

785

2,364

2,092

272

Adjusted pre-tax income (2)

985

1,278

(293)

1,262

1,740

(478)

Adjusted net income (2) 

969

1,281

(312)

1,242

1,757

(515)

Total liquidity (3)

10,261

9,949

312

10,261

9,949

312

Net cash flows from operating activities  

737

408

329

3,253

3,335

(82)

Free cash flow (2) 

282

135

147

1,789

2,087

(298)

Net debt (2)

3,426

5,438

(2,012)

3,426

5,438

(2,012)

Diluted earnings per share  

5.38

3.08

2.30

6.25

5.55

0.70

Adjusted earnings per share – diluted (2)

2.57

3.41

(0.84)

3.30

4.67

(1.37)

Operating Statistics (4)

2024

2023

Change
%

2024

2023

Change
%

Revenue passenger miles (RPMs) (millions)

25,101

25,202

(0.4)

68,070

65,397

4.1

Available seat miles (ASMs) (millions)

28,892

28,060

3.0

79,432

74,573

6.5

Passenger load factor %

86.9 %

89.8 %

(2.9) pp

85.7 %

87.7 %

(2.0) pp

Passenger revenue per RPM (Yield) (cents)

22.3

23.3

(4.0)

22.1

22.7

(3.0)

Passenger revenue per ASM (PRASM) (cents)

19.4

20.9

(7.2)

18.9

19.9

(5.0)

Operating revenue per ASM (TRASM) (cents)

21.1

22.6

(6.5)

21.2

22.3

(5.0)

Operating expense per ASM (CASM) (cents)

17.5

17.6

(0.2)

19.3

19.4

(0.4)

Adjusted CASM (cents) (2)

12.2

12.2

(0.4)

13.4

13.2

1.2

Average number of full-time-equivalent (FTE) employees (thousands) (5)

37.2

35.9

3.7

37.1

35.4

4.7

Aircraft in operating fleet at period-end

353

354

(0.3)

353

354

(0.3)

Seats dispatched (thousands)

15,258

14,707

3.7

42,950

40,390

6.3

Aircraft frequencies (thousands)

104.5

101.0

3.5

293.4

279.7

4.9

Average stage length (miles) (6)

1,894

1,908

(0.7)

1,849

1,846

0.2

Fuel cost per litre (cents)

98.2

101.9

(3.7)

102.5

109.6

(6.5)

Fuel litres (thousands)

1,399,170

1,342,967

4.2

3,857,355

3,572,766

8.0

Revenue passengers carried (thousands) (7)

12,618

12,635

(0.1)

34,957

33,891

3.1



(1)

Operating margin is a supplementary financial measure and is defined as operating income (loss) as a percentage of operating revenues.

(2)

Adjusted pre-tax income (loss), adjusted net income (loss), adjusted earnings (loss) per share, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), adjusted EBITDA margin, free cash flow, net debt and adjusted CASM are non-GAAP financial measures, capital management measures, non-GAAP ratios or supplementary financial measures. Such measures are not recognized measures for financial statement presentation under GAAP, do not have standardized meanings, may not be comparable to similar measures presented by other entities and should not be considered a substitute for or superior to GAAP results. Refer to section “Non-GAAP Financial Measures” of this release for descriptions of Air Canada’s non-GAAP financial measures and for a quantitative reconciliation of Air Canada’s non-GAAP financial measures to the most comparable GAAP measure.

(3)

Total liquidity refers to the sum of cash, cash equivalents, short- and long-term investments, and the amounts available under Air Canada’s credit facilities. Total liquidity, as at September 30, 2024, of $10,261 million consisted of $8,942 million in cash, cash equivalents, short- and long-term investments and $1,319 million available under undrawn credit facilities. As at September 30, 2023, total liquidity of $9,949 million consisted of $8,934 million in cash, cash equivalents, short- and long-term investments and $1,015 million available under undrawn credit facilities. Total liquidity also includes funds ($243 million as at September 30, 2024, and $240 million as at September 30, 2023) held in trust by Air Canada Vacations in accordance with regulatory requirements governing advance sales for tour operators.

(4)

Except for the reference to average number of FTE employees, operating statistics in this table include third-party carriers operating under capacity purchase agreements with Air Canada.

(5)

Reflects FTE employees at Air Canada and its subsidiaries. Excludes FTE employees at third-party carriers operating under capacity purchase agreements with Air Canada.

(6)

Average stage length is calculated by dividing the total number of available seat miles by the total number of seats dispatched.

(7)

Revenue passengers are counted on a flight number basis (rather than by journey/itinerary or by leg), which is consistent with the IATA definition of revenue passengers carried.

(8)

“pp” denotes percentage points and refers to a measure of the arithmetic difference between two percentages.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/air-canada-reports-third-quarter-2024-financial-results-302293591.html

SOURCE Air Canada

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Apple, Amazon And 3 Stocks To Watch Heading Into Friday

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:

  • Wall Street expects Chevron Corporation CVX to report quarterly earnings at $2.43 per share on revenue of $48.99 billion before the opening bell, according to data from Benzinga Pro. Chevron shares fell 0.5% to $148.04 in after-hours trading.
  • Apple Inc. AAPL reported better-than-expected earnings and sales results for the fourth quarter. The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share. Apple shares fell 1.8% to $221.74 in the after-hours trading session.
  • Analysts are expecting Exxon Mobil Corporation XOM to post quarterly earnings at $1.88 per share on revenue of $93.94 billion. The company will release earnings before the markets open. Exxon Mobil shares fell 0.04% to $116.73 in after-hours trading.

Check out our premarket coverage here

  • Amazon.com Inc. AMZN posted stronger-than-expected results for the third quarter on Thursday. Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year. Amazon shares jumped 6% to $197.50 in the after-hours trading session.
  • Analysts expect Cardinal Health, Inc. CAH to report quarterly earnings at $1.62 per share on revenue of $50.9 billion before the opening bell. Cardinal Health shares gained 0.1% to $108.65 in after-hours trading.

Check This Out:

Photo courtesy: Shutterstock

Market News and Data brought to you by Benzinga APIs

Waters Corporation (NYSE: WAT) Reports Third Quarter 2024 Financial Results

Highlights

  • Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currency
  • Instruments returned to growth; recurring revenue grew high single-digits in constant currency
  • All reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & Industrial
  • GAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditions
  • Raised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarter

Third Quarter 2024

MILFORD, Mass., Nov. 1, 2024 /PRNewswire/ — Waters Corporation WAT today announced its financial results for the third quarter of 2024.

Sales for the third quarter of 2024 were $740 million, an increase of 4% as reported, compared to sales of $712 million for the third quarter of 2023. Currency translation had minimal impact on sales.

On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2024 was $2.71, compared to $2.27 for the third quarter of 2023. On a non-GAAP basis, EPS was $2.93, compared to $2.84 for the third quarter of 2023. This includes a headwind of approximately 2% due to unfavorable foreign exchange.

“We delivered exceptional third quarter results, fueled by new product adoption and improved customer spending trends,” said Dr. Udit Batra, President & CEO, Waters Corporation. “Instruments returned to growth sooner than expected, as liquid chromatography sales to pharma and industrial customers turned positive.”

Dr. Batra continued, “Looking ahead, our strong commercial execution, competitive product portfolio, and excellent operational performance give us confidence in the long-term outlook for Waters.”

Other Highlights

During the third quarter of 2024, sales into the pharmaceutical market increased 2% as reported and 3% in constant currency. Sales into the industrial market increased 9% as reported and 7% in constant currency. Sales into the academic and government market increased 2% as reported and were flat in constant currency.

During the quarter, instrument system sales increased 1% as reported and in constant currency. Recurring revenues, which represent the combination of service and precision chemistries, increased 6% as reported and 7% in constant currency.

Geographically, sales in Asia during the quarter increased 5% as reported and 6% in constant currency. Sales in the Americas increased 1% as reported and in constant currency. Sales in Europe increased 6% as reported and 4% in constant currency.

Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company’s website www.waters.com in the Investor Relations section.

Full-Year and Fourth Quarter 2024 Financial Guidance

Full-Year 2024 Financial Guidance

The Company is raising its full-year 2024 sales guidance, and now expects organic constant currency sales growth to be in the range of -0.9% to -0.3%. Currency translation is expected to decrease full-year sales growth by 1.2%. M&A contribution from the Wyatt transaction covering the first four-and-a-half months of the year has added 1.3% to full-year reported sales. The resulting full-year 2024 reported sales growth is expected in the range of -0.8% to -0.2%.

The Company is also raising its full-year 2024 non-GAAP EPS guidance to now be in the range of $11.67 to $11.87, which includes an estimated headwind of approximately 3% due to unfavorable foreign exchange.

Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full year.

Fourth Quarter 2024 Financial Guidance

The Company expects fourth quarter 2024 constant currency sales growth to be in the range of +5.0% to +7.0%. Currency translation is expected to decrease fourth quarter sales growth by 1.7%. The resulting fourth quarter 2024 reported sales growth is expected in the range of +3.3% to +5.3%.

The Company expects fourth quarter 2024 non-GAAP EPS to be in the range of $3.90 to $4.10, which includes an estimated headwind of approximately 3% due to unfavorable foreign exchange.

Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the fourth quarter.

Conference Call Details

Waters Corporation will webcast its third quarter 2024 financial results conference call today, November 1, 2024, at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select “Investor Relations” under the “About Waters” section, navigate to “Events & Presentations,” and click on the “Webcast.” A replay will be available through November 29, 2024, on the same website by webcast and also by phone at (888) 282-0031.

About Waters Corporation

Waters Corporation WAT, a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.

Non-GAAP Financial Measures

This press release contains financial measures, such as organic constant currency growth rates, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects” and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company’s actual future results may differ significantly from the results discussed in the forward- looking statements within this release for a variety of reasons, including and without limitation, risks related to, and expectations or ability to realize commercial success of the Wyatt transaction; the impact of this transaction on the Company’s business, anticipated progress on Waters’ research programs, development of new analytical instruments and associated software or consumables, manufacturing development and capabilities; the increased indebtedness of the Company as a result of the Wyatt transaction, the repayment of which could impact the Company’s future results, market prospects for its products and sales and earnings guidance; foreign currency exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results, particularly when a foreign currency weakens against the U.S. dollar; current global economic, sovereign and political conditions and uncertainties, including the effect of new or proposed tariff or trade regulations as well as other new or changed domestic and foreign laws, regulations and policies; changes in inflation and interest rates; the impacts and costs of war, in particular as a result of the ongoing conflicts between Russia and Ukraine and in the Middle East, and the possibility of further escalation resulting in new geopolitical and regulatory instability; the Chinese government’s ongoing tightening of restrictions on procurement by government-funded customers; the Company’s ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions; risks related to the effects of any pandemic on our business, financial condition, results of operations and prospects; changes in timing and demand for the Company’s products among the Company’s customers and various market sectors, particularly as a result of fluctuations in their expenditures or ability to obtain funding; the ability to realize the expected benefits related to the Company’s various cost-saving initiatives, including workforce reductions and organizational restructurings; the introduction of competing products by other companies and loss of market share, as well as pressures on prices from competitors and/or customers; changes in the competitive landscape as a result of changes in ownership, mergers and continued consolidation among the Company’s competitors; regulatory, economic and competitive obstacles to new product introductions; lack of acceptance of new products and inability to grow organically through innovation; rapidly changing technology and product obsolescence; risks associated with previous or future acquisitions, strategic investments, joint ventures and divestitures, including risks associated with achieving the anticipated financial results and operational synergies; contingent purchase price payments and expansion of our business into new or developing markets; risks associated with unexpected disruptions in operations; failure to adequately protect the Company’s intellectual property, infringement of intellectual property rights of third parties and inability to obtain licenses on commercially reasonable terms; the Company’s ability to acquire adequate sources of supply and its reliance on outside contractors for certain components and modules, as well as disruptions to its supply chain; risks associated with third-party sales intermediaries and resellers; the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates as well as shifts in taxable income among jurisdictions with different effective tax rates, the outcome of ongoing and future tax examinations and changes in legislation affecting the Company’s effective tax rate; the Company’s ability to attract and retain qualified employees and management personnel; risks associated with cybersecurity and technology, including attempts by third parties to defeat the security measures of the Company and its third-party partners; increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others, and in connection with government contracts; regulatory, environmental and logistical obstacles affecting the distribution of the Company’s products, completion of purchase order documentation and the ability of customers to obtain letters of credit or other financing alternatives; risks associated with litigation and other legal and regulatory proceedings; and the impact and costs incurred from changes in accounting principles and practices. Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2023, as well as in the sections entitled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” of the Company’s quarterly reports on Form 10-Q for the quarterly periods ended March 30, 2024 and June 29, 2024, as filed with the Securities and Exchange Commission (“SEC”), which discussions are incorporated by reference in this release, as updated by the Company’s future filings with the SEC. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

Waters Corporation and Subsidiaries

Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)
















Three Months Ended


Nine Months Ended


September 28,
2024


September 30,
2023


September 28,
2024


September 30,
2023









Net sales

$               740,305


$               711,692


$            2,085,673


$            2,136,942









Costs and operating expenses:








Cost of sales

301,655


291,407


851,685


876,863

Selling and administrative expenses 

169,097


186,748


516,880


555,657

Research and development expenses 

45,336


41,995


136,113


130,559

Purchased intangibles amortization 

11,759


12,116


35,337


20,410

Litigation provision

1,326



11,568










Operating income 

211,132


179,426


534,090


553,453









Other (expense) income, net

(338)


328


1,619


1,364

Interest expense, net

(17,177)


(26,559)


(57,824)


(56,174)









Income from operations before income taxes

193,617


153,195


477,885


498,643









Provision for income taxes

32,114


18,643


71,449


72,614









Net income

$               161,503


$               134,552


$               406,436


$               426,029

















Net income per basic common share

$                     2.72


$                     2.28


$                     6.85


$                     7.21









Weighted-average number of basic common shares

59,367


59,093


59,314


59,061

















Net income per diluted common share

$                     2.71


$                     2.27


$                     6.83


$                     7.19









Weighted-average number of diluted common shares and equivalents

59,504


59,255


59,471


59,262

 

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segments, Products & Services, Geography and Markets

Three Months Ended September 28, 2024 and September 30, 2023

(In thousands)

































Constant






Three Months Ended


Percent


Impact of


Currency






September 28, 2024


September 30, 2023


Change


Currency


Growth Rate (a)

















NET SALES – OPERATING SEGMENTS





























Waters



$

655,652


$

629,348


4 %


0 %


4 %

TA





84,653



82,344


3 %


1 %


2 %

















Total




$

740,305


$

711,692


4 %


0 %


4 %

































NET SALES – PRODUCTS & SERVICES





























Instruments



$

323,076


$

319,431


1 %


0 %


1 %

















Service




278,294



263,611


6 %


0 %


6 %

Chemistry




138,935



128,650


8 %


0 %


8 %

Total Recurring




417,229



392,261


6 %


(1 %)


7 %

















Total




$

740,305


$

711,692


4 %


0 %


4 %

































NET SALES – GEOGRAPHY





























Asia




$

251,329


$

238,228


5 %


(1 %)


6 %

Americas




279,136



275,479


1 %


0 %


1 %

Europe




209,840



197,985


6 %


2 %


4 %

















Total




$

740,305


$

711,692


4 %


0 %


4 %

































NET SALES – MARKETS





























Pharmaceutical



$

430,138


$

421,535


2 %


(1 %)


3 %

Industrial




227,740



209,449


9 %


2 %


7 %

Academic & Government



82,427



80,708


2 %


2 %


0 %

















Total




$

740,305


$

711,692


4 %


0 %


4 %

































(a)

The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

 


Waters Corporation and Subsidiaries


Reconciliation of GAAP to Adjusted Non-GAAP


Net Sales by Operating Segments, Products & Services, Geography and Markets


Nine Months Ended September 28, 2024 and September 30, 2023


(In thousands)





















Organic 



















Constant







Nine Months Ended


Percent


Impact of


Impact of


Currency







September 28, 2024


September 30, 2023


Change


Currency


Acquisitions


Growth Rate (a)





















NET SALES – OPERATING SEGMENTS



































Waters



$

1,840,112


$

1,884,658


(2 %)


(1 %)


2 %


(3 %)


TA





245,561



252,284


(3 %)


(1 %)


0 %


(2 %)





















Total




$

2,085,673


$

2,136,942


(2 %)


(1 %)


2 %


(3 %)








































NET SALES – PRODUCTS & SERVICES



































Instruments



$

859,079


$

964,380


(11 %)


0 %


3 %


(14 %)





















Service




812,367



774,478


5 %


(1 %)


1 %


5 %


Chemistry




414,227



398,084


4 %


(1 %)


0 %


5 %


Total Recurring




1,226,594



1,172,562


5 %


(1 %)


1 %


5 %





















Total




$

2,085,673


$

2,136,942


(2 %)


(1 %)


2 %


(3 %)








































NET SALES – GEOGRAPHY



































Asia




$

696,319


$

745,932


(7 %)


(3 %)


1 %


(5 %)


Americas




794,775



804,827


(1 %)


0 %


3 %


(4 %)


Europe




594,579



586,183


1 %


2 %


2 %


(3 %)





















Total




$

2,085,673


$

2,136,942


(2 %)


(1 %)


2 %


(3 %)








































NET SALES – MARKETS



































Pharmaceutical



$

1,220,092


$

1,233,177


(1 %)


(1 %)


2 %


(2 %)


Industrial




644,459



648,754


(1 %)


0 %


1 %


(2 %)


Academic & Government



221,122



255,011


(13 %)


1 %


2 %


(16 %)





















Total




$

2,085,673


$

2,136,942


(2 %)


(1 %)


2 %


(3 %)








































(a)

The Company believes that referring to comparable organic constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Organic constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. See description of non-GAAP financial measures contained in this release.

 

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP Financials

Three and Nine Months Ended September 28, 2024 and September 30, 2023

(In thousands, except per share data)



















































Income from






























Operations















Selling &



Research &






Operating



Other



before



Provision for






Diluted






Administrative



Development



Operating



Income



(Expense)



Income



Income



Net



Earnings






Expenses(a)



Expenses



Income



Percentage



Income



Taxes



Taxes



Income



per Share

Three Months Ended September 28, 2024




























GAAP



$

182,182


$

45,336


$

211,132



28.5 %


$

(338)


$

193,617


$

32,114


$

161,503


$

2.71

Adjustments:






























Purchased intangibles amortization (b)



(11,759)





11,759



1.6 %





11,759



2,814



8,945



0.15


Litigation provision (c)



(1,326)





1,326



0.2 %





1,326



318



1,008



0.02


Restructuring costs and certain other items (d)



(1,194)





1,194



0.2 %





1,194



282



912



0.02


Retention bonus obligation (f)



(1,909)



(636)



2,545



0.3 %





2,545



611



1,934



0.03

Adjusted Non-GAAP


$

165,994


$

44,700


$

227,956



30.8 %


$

(338)


$

210,441


$

36,139


$

174,302


$

2.93































Three Months Ended September 30, 2023




























GAAP



$

198,864


$

41,995


$

179,426



25.2 %


$

328


$

153,195


$

18,643


$

134,552


$

2.27

Adjustments:






























Purchased intangibles amortization (b)



(12,116)





12,116



1.7 %





12,116



2,901



9,215



0.16


Restructuring costs and certain other items (d)



(24,057)





24,057



3.4 %



(651)



23,406



5,387



18,019



0.30


Acquisition related costs (e)



(1,263)





1,263



0.2 %





1,263



303



960



0.02


Retention bonus obligation (f)



(5,725)



(1,909)



7,634



1.1 %





7,634



1,832



5,802



0.10

Adjusted Non-GAAP


$

155,703


$

40,086


$

224,496



31.5 %


$

(323)


$

197,614


$

29,066


$

168,548


$

2.84































Nine Months Ended September 28, 2024




























GAAP



$

563,785


$

136,113


$

534,090



25.6 %


$

1,619


$

477,885


$

71,449


$

406,436


$

6.83

Adjustments:






























Purchased intangibles amortization (b)



(35,337)





35,337



1.7 %





35,337



8,456



26,881



0.45


Litigation provision and settlement (c)



(11,568)





11,568



0.6 %





11,568



2,776



8,792



0.15


Restructuring costs and certain other items (d)



(10,680)





10,680



0.5 %





10,680



2,617



8,063



0.14


Retention bonus obligation (f)



(11,451)



(3,817)



15,268



0.7 %





15,268



3,664



11,604



0.20

Adjusted Non-GAAP


$

494,749


$

132,296


$

606,943



29.1 %


$

1,619


$

550,738


$

88,962


$

461,776


$

7.76































Nine Months Ended September 30, 2023




























GAAP



$

576,067


$

130,559


$

553,453



25.9 %


$

1,364


$

498,643


$

72,614


$

426,029


$

7.19

Adjustments:






























Purchased intangibles amortization (b)



(20,410)





20,410



1.0 %





20,410



4,852



15,558



0.26


Restructuring costs and certain other items (d)



(28,881)





28,881



1.4 %



(651)



28,230



6,860



21,370



0.36


Acquisition related costs (e)



(13,298)





13,298



0.6 %





13,298



3,191



10,107



0.17


Retention bonus obligation (f)



(8,368)



(2,790)



11,158



0.5 %





11,158



2,678



8,480



0.14

Adjusted Non-GAAP


$

505,110


$

127,769


$

627,200



29.4 %


$

713


$

571,739


$

90,195


$

481,544


$

8.13































________________________________

(a)

Selling & administrative expenses include purchased intangibles amortization and litigation provisions and settlements.

(b)

The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

(c)

Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly.

(d)

Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

(e)

Acquisition related costs include all incremental expenses incurred, such as advisory, legal, accounting, tax, valuation, and other professional fees. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

(f)

In connection with the Wyatt acquisition, the Company started to recognize a two-year retention bonus obligation that is contingent upon the employee’s providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

 

Waters Corporation and Subsidiaries

Preliminary Condensed Unclassified Consolidated Balance Sheets

(In thousands and unaudited)






























September 28, 2024


December 31, 2023









Cash, cash equivalents and investments


$                331,458


$                395,974

Accounts receivable




669,534


702,168

Inventories




518,994


516,236

Property, plant and equipment, net


642,627


639,073

Intangible assets, net



591,883


629,187

Goodwill





1,306,593


1,305,446

Other assets




450,531


438,770

   Total assets




$             4,511,620


$             4,626,854

















Notes payable and debt



$             1,826,248


$             2,355,513

Other liabilities




1,082,273


1,121,000

   Total liabilities




2,908,521


3,476,513









Total stockholders’ equity



1,603,099


1,150,341

   Total liabilities and stockholders’ equity


$             4,511,620


$             4,626,854

 

Waters Corporation and Subsidiaries

Preliminary Condensed Consolidated Statements of Cash Flows

Three and Nine Months Ended September 28, 2024 and September 30, 2023

(In thousands and unaudited)

















Three Months Ended



Nine Months Ended





September 28, 2024


September 30, 2023



September 28, 2024


September 30, 2023









Cash flows from operating activities:










Net income

$                     161,503


$                   134,552



$                   406,436


$                   426,029


Adjustments to reconcile net income to net












cash provided by operating activities:











Stock-based compensation

10,647


8,490



32,993


32,224



Depreciation and amortization

47,507


47,807



143,250


117,845



Change in operating assets and liabilities and other, net

(15,077)


(33,031)



(60,695)


(203,411)




Net cash provided by operating activities

204,580


157,818



521,984


372,687













Cash flows from investing activities:










Additions to property, plant, equipment












and software capitalization

(25,618)


(38,047)



(90,377)


(119,044)


Business acquisitions, net of cash acquired





(1,285,907)


(Investments in) proceeds from unaffiliated companies

(425)


651



(1,489)


651


Net change in investments

(8)


(5)



(44)


(21)




Net cash used in investing activities

(26,051)


(37,401)



(91,910)


(1,404,321)













Cash flows from financing activities:










Net change in debt

(180,000)


(125,181)



(530,000)


929,601


Proceeds from stock plans

3,237


9,464



25,073


18,092


Purchases of treasury shares

(141)


(692)



(13,475)


(70,433)


Other cash flow from financing activities, net

20


2,884



15,305


8,178




Net cash used in financing activities

(176,884)


(113,525)



(503,097)


885,438













Effect of exchange rate changes on cash and cash equivalents

2,442


(171)



8,461


2,081




Increase (decrease) in cash and cash equivalents

4,087


6,721



(64,562)


(144,115)













Cash and cash equivalents at beginning of period

326,427


329,693



395,076


480,529




Cash and cash equivalents at end of period

$                     330,514


$                   336,414



$                   330,514


$                   336,414

















































Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)





































Net cash provided by operating activities – GAAP

$                     204,580


$                   157,818



$                   521,984


$                   372,687














Adjustments:











Additions to property, plant, equipment












and software capitalization

(25,618)


(38,047)



(90,377)


(119,044)



Tax reform payments




95,645


72,101



Litigation settlements (received) paid, net


(375)



9,250


(1,125)



Major facility renovations


3,291




12,151



Payment of acquired Wyatt liabilities (b)





25,617



Payment of Wyatt retention bonus obligation (c)




19,770


Free Cash Flow – Adjusted Non-GAAP

$                     178,962


$                   122,687



$                   556,272


$                   362,387













(a)

The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.













(b)

In connection with the Wyatt acquisition, the Company assumed certain obligations of Wyatt and paid those obligations immediately upon closing the transaction. The Company believes that the assumed obligations do not represent future ongoing business expenses.













(c)

During the nine months ended September 28, 2024, the Company made its first retention payment under the Wyatt retention bonus program. The Company believes that these payments are not normal and do not represent future ongoing business expenses.

 

Waters Corporation and Subsidiaries

Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook
























Twelve Months Ended


Three Months Ended




December 31, 2024


December 31, 2024





Range




Range


Projected Sales


















Organic constant currency sales growth rate (a)

(0.9 %)

(0.3 %)


5.0 %

7.0 %

Impact of:










Currency translation

(1.2 %)

(1.2 %)


(1.7 %)

(1.7 %)


Acquisitions

1.3 %

1.3 %


Sales growth rate as reported

(0.8 %)

(0.2 %)


3.3 %

5.3 %

























Range




Range


Projected Earnings Per Diluted Share


















GAAP earnings per diluted share

$    10.55

$    10.75


$      3.72

$      3.92

Adjustments:










Purchased intangibles amortization 

$      0.60

$      0.60


$      0.15

$      0.15


Litigation settlement

$      0.15

$      0.15


$            –

$            –


Restructuring costs and certain other items 

$      0.14

$      0.14


$            –

$            –


Retention bonus obligation

$      0.23

$      0.23


$      0.03

$      0.03

Adjusted non-GAAP earnings per diluted share

$    11.67

$    11.87


$      3.90

$      4.10











(a) Organic constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results.











These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.

 

Contact:    Caspar Tudor, Head of Investor Relations – (508) 482-2429

Cision View original content:https://www.prnewswire.com/news-releases/waters-corporation-nyse-wat-reports-third-quarter-2024-financial-results-302293299.html

SOURCE Waters Corporation

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

S&P 500 Records Worst Session In Over A Month, Meta And Microsoft Tumble: Greed Index Moves To 'Fear' Zone

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the “Fear” zone on Thursday.

U.S. stocks settled lower on Thursday, with the Nasdaq Composite falling more than 500 points during the session. The S&P 500 and Nasdaq both recorded their biggest single-day declines since Sept. 3.

Shares of Meta Platforms Inc. META fell around 4% on Thursday after the company reported third-quarter financial results. Shares of Microsoft Corp. MSFT fell around 6% on Thursday after the company reported first-quarter financial results.

On the economic data front, U.S. initial jobless claims declined by 12,000 from the previous week to 216,000 in the week ending Oct. 26. The personal consumption expenditure price index rose 0.2% month-over-month in September following a 0.1% increase in August.

Most sectors on the S&P 500 closed on a negative note, with information technology, consumer discretionary, and real estate stocks recording the biggest losses on Thursday. However, utilities and energy stocks bucked the overall market trend, closing the session higher.

The Dow Jones closed lower by around 378 points to 41,763.46 on Thursday. The S&P 500 fell 1.86% to 5,705.45, while the Nasdaq Composite fell 2.76% at 18,095.15 during Thursday’s session.

Investors are awaiting earnings results from Chevron Corporation CVX, Exxon Mobil Corporation XOM, and Cardinal Health, Inc. CAH today.

What is CNN Business Fear & Greed Index?

At a current reading of 43.5, the index moved to the “Fear” zone on Thursday, versus a prior reading of 54.

The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.

Read Next:

Photo courtesy: Shutterstock

Market News and Data brought to you by Benzinga APIs

BrightSpring Health Services, Inc. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Guidance

LOUISVILLE, Ky., Nov. 01, 2024 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) BTSG, a leading provider of home and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2024, and increases 2024 revenue and Adjusted EBITDA1 guidance.

Financial Highlights

  • Net Revenue of $2,907 million, up 28.8% compared to $2,257 million in the third quarter of 2023.
  • Net loss of $9.0 million, compared to net loss of $130.1 million in the third quarter of 2023.
  • Adjusted EBITDA1 of $151 million, up 15.7% versus $131 million in the third quarter of 2023
  • Increased 2024 Revenue and Adjusted EBITDA Guidance:
    • Revenue: $11,000 – $11,300 million
    • Adjusted EBITDA1: $580 – $585 million

“We are pleased with the broad-based strength in revenue and earnings growth across Pharmacy Solutions and Providers Services in the third quarter,” said Jon Rousseau, Chairman, President and Chief Executive Officer of the Company. “At BrightSpring we are focused on driving operational excellence and efficiencies while increasing scale across our organization to deliver lower-cost and high-quality care to patients. We are confident that the Company remains well positioned to execute on providing a high level of quality care to patients and continuing to grow our businesses for the remainder of 2024 and in 2025.”

Third Quarter 2024 Financial Results

Net revenue of $2,907 million, up 28.8% compared to $2,257 million in the third quarter of 2023. Net revenue growth was driven by strength across the business, with robust growth in Specialty and Infusion Pharmacy.

Gross profit of $408 million, up 13.9% compared to $358 million in the third quarter of 2023.

Net loss of $9.0 million, compared to net loss of $130.1 million in the third quarter of 2023.

Adjusted EBITDA1 of $151 million, up 15.7% compared to $131 million in the third quarter of 2023

1Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” and the end of this press release for a reconciliation of Adjusted EBITDA to net loss, the most directly comparable financial measure prepared in accordance with GAAP.

Key Financials:

  Three Months Ended        
  September 30, (Unaudited)        
  2024      2023     %
($ in millions)                      
Pharmacy Solutions Revenue $ 2,266     $ 1,673       35%  
Provider Services Revenue   641       583       10%  
Total Revenue $  2,907     $  2,257        29%  
                       
  Three Months Ended        
  September 30, (Unaudited)        
  2024      2023      %
($ in millions)                      
Pharmacy Solutions segment EBITDA $ 99     $ 86       15%  
Provider Services segment EBITDA   93       81       14%  
Total Segment Adjusted EBITDA $ 192     $ 168       14%  
Corporate Costs   (41)       (37)        
Total Company Adjusted EBITDA $ 151     $ 131       15.7%  
                       

Full Year 2024 Financial Guidance

For the full year 2024, BrightSpring is increasing guidance, which excludes the effects of any future closed acquisitions.

  • Net revenue of $11,000 million to $11,300 million, or 24.6% to 28.0% growth over 2023
    • Pharmacy Segment Revenue of $8,500 million to $8,750 million, or 30.3% to 34.2% growth over full year 2023
    • Provider Segment Revenue of $2,500 million to $2,550 million, or 8.5% to 10.7% growth over full year 2023
  • Adjusted EBITDA2 of $580 million to $585 million, or 14.2% to 15.2% growth over full year 2023, excluding the impact from a certain Quality Incentive Payment in 2023

A copy of the Company’s third quarter earnings presentation is available on the company’s investor relations website, https://ir.brightspringhealth.com/

2 A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net loss cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

Webcast and Conference Call Details

BrightSpring will host a conference call today, November 1, 2024, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online.

A live and archived webcast of the event will be available on the “Events & Presentations” section of the BrightSpring website at https://ir.brightspringhealth.com/. The Company has posted supplemental financial information on the third quarter results that it will reference during the conference call. The supplemental information can be found under the “Events & Presentations” on the Company’s investor relations page.

About BrightSpring Health Services

BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, we have used words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” “target,” “guidance,” the negative version of these words, or similar terms and phrases to identify these forward-looking statements.

The forward-looking statements are based on management’s current expectations and are not historical facts or guarantees of future performance. The forward-looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:

  • our operation in a highly competitive industry;
  • our inability to maintain relationships with existing patient referral sources or establish new referral sources;
  • changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;
  • cost containment initiatives of third-party payors, including post-payment audits;
  • the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;
  • changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;
  • our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;
  • changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;
  • changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;
  • reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;
  • compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;
  • fluctuation of our results of operations on a quarterly basis;
  • harm caused by labor relation matters;
  • limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;
  • delays in collection or non-collection of our accounts receivable, particularly during the business integration process;
  • failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;
  • our ability to identify, successfully complete and manage acquisitions, joint ventures, and other strategic initiatives;
  • our ability to continue to provide consistently high quality of care;
  • maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;
  • contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;
  • effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;
  • security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;
  • risks related to credit card payments and other payment methods;
  • potential substantial malpractice or other similar claims;
  • various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;
  • our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;
  • factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;
  • a pandemic, epidemic, or outbreak of an infectious disease, including the ongoing effects of COVID-19;
  • inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations;
  • our inability to adequately protect our intellectual property rights

The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.

For additional information on these and other factors that could cause BrightSpring’s actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures,” including “EBITDA” and “Adjusted EBITDA,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.

EBITDA and Adjusted EBITDA have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA and Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.

Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA and Adjusted EBITDA are not GAAP measures of our financial performance and should not be considered as an alternative to net loss as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.

Management defines EBITDA as net loss before income tax expense (benefit), interest expense, and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, goodwill impairment, legal costs and settlements associated with certain historical matters for PharMerica, significant projects, management fees, and unreimbursed COVID-19 related costs.

The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP.

BrightSpring Contact:

Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
ir@brightspringhealth.com

Media Contact:
Leigh White
leigh.white@brightspringhealth.com
502.630.7412

           
BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
September 30, 2024 and December 31, 2023
(In thousands, except share and per share data)
(Unaudited)
           
  September 30, 2024     December 31, 2023  
Assets          
Current assets:          
Cash and cash equivalents $ 35,973     $ 13,071  
Accounts receivable, net of allowance for credit losses   1,025,711       881,627  
Inventories   478,319       402,776  
Prepaid expenses and other current assets   169,582       159,167  
Total current assets   1,709,585       1,456,641  
Property and equipment, net of accumulated depreciation of $426,484 and $368,089 at September 30, 2024 and December 31, 2023, respectively   248,548       245,908  
Goodwill   2,672,791       2,608,412  
Intangible assets, net of accumulated amortization   842,479       881,476  
Operating lease right-of-use assets, net   259,138       267,446  
Deferred income taxes, net   6,678        
Other assets   46,748       72,838  
Total assets $ 5,785,967     $ 5,532,721  
Liabilities, Redeemable Noncontrolling Interests, and Equity          
Current liabilities:          
Trade accounts payable $ 783,838     $ 641,607  
Accrued expenses   349,101       492,363  
Current portion of obligations under operating leases   69,763       71,053  
Current portion of obligations under financing leases   12,367       11,141  
Current portion of long-term debt   48,853       32,273  
Total current liabilities   1,263,922       1,248,437  
Obligations under operating leases, net of current portion   195,921       201,655  
Obligations under financing leases, net of current portion   24,988       22,528  
Long-term debt, net of current portion   2,608,537       3,331,941  
Deferred income taxes, net         23,668  
Long-term liabilities   73,502       91,943  
Total liabilities   4,166,870       4,920,172  
Redeemable noncontrolling interests   4,125       27,139  
Shareholders’ equity:          
Common stock, $0.01 par value, 1,500,000,000 and 137,398,625 shares authorized, 174,078,977 and 117,857,055 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively   1,741       1,179  
Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and outstanding at September 30, 2024; no shares authorized, issued or outstanding at December 31, 2023          
Additional paid-in capital   1,848,115       771,336  
Accumulated deficit   (234,380 )     (200,319 )
Accumulated other comprehensive (loss) income   (705 )     12,544  
Total shareholders’ equity   1,614,771       584,740  
Noncontrolling interest   201       670  
Total equity   1,614,972       585,410  
Total liabilities, redeemable noncontrolling interests, and equity $ 5,785,967     $ 5,532,721  
               
BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
For the three and nine months ended September 30, 2024 and 2023
(In thousands, except per share amounts)
(Unaudited)
           
  For the Three Months Ended     For the Nine Months Ended  
  September 30,     September 30,  
  2024     2023     2024     2023  
Revenues:                      
Products $ 2,265,697     $ 1,673,152     $ 6,357,223     $ 4,736,993  
Services   641,126       583,377       1,856,448       1,714,638  
Total revenues   2,906,823       2,256,529       8,213,671       6,451,631  
Cost of goods   2,077,121       1,509,845       5,815,981       4,226,075  
Cost of services   421,590       388,388       1,231,154       1,160,477  
Gross profit   408,112       358,296       1,166,536       1,065,079  
Selling, general, and administrative expenses   351,272       410,549       1,039,215       986,161  
Operating income (loss)   56,840       (52,253 )     127,321       78,918  
Loss on extinguishment of debt               12,726        
Interest expense, net   56,061       83,678       173,520       241,539  
Income (loss) before income taxes   779       (135,931 )     (58,925 )     (162,621 )
Income tax expense (benefit)   9,760       (5,807 )     (23,000 )     (12,987 )
Net loss   (8,981 )     (130,124 )     (35,925 )     (149,634 )
Net (loss) income attributable to noncontrolling interests   (751 )     548       (1,864 )     (1,568 )
Net loss attributable to BrightSpring Health Services, Inc. and subsidiaries $ (8,230 )   $ (130,672 )   $ (34,061 )   $ (148,066 )
                       
Net loss per common share:                      
Loss per share – basic $ (0.04 )   $ (1.11 )   $ (0.18 )   $ (1.26 )
Loss per share – diluted $ (0.04 )   $ (1.11 )   $ (0.18 )   $ (1.26 )
Weighted average shares outstanding:                      
Basic   198,491       117,864       190,541       117,871  
Diluted   198,491       117,864       190,541       117,871  
                               
BrightSpring Health Services, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
For the three and nine months ended September 30, 2024 and 2023
(In thousands)
(Unaudited)
           
  For the Three Months Ended     For the Nine Months Ended  
  September 30,     September 30,  
  2024     2023     2024     2023  
Operating activities:                      
Net loss $ (8,981 )   $ (130,124 )   $ (35,925 )   $ (149,634 )
Adjustments to reconcile net loss to cash provided by (used in) operating activities:                              
Depreciation and amortization   50,608       50,774       149,601       151,324  
Impairment of long-lived assets   2,801       2,181       4,781       8,295  
Provision for credit losses   8,778       6,753       21,896       18,927  
Amortization of deferred debt issuance costs   2,540       5,182       9,477       15,691  
Share-based compensation   15,210       825       55,194       2,100  
Deferred income taxes, net   21,479       (10,810 )     (27,781 )     (36,565 )
Loss on extinguishment of debt               12,726        
(Gain) loss on disposition of fixed assets   (79 )     438       (55 )     957  
Other   479       (582 )     (959 )     (210 )
Change in operating assets and liabilities, net of acquisitions and dispositions:                              
Accounts receivable   (51,474 )     (11,520 )     (163,996 )     (116,922 )
Prepaid expenses and other current assets   (24,207 )     (22,272 )     (2,470 )     (162 )
Inventories   (103,985 )     16,536       (74,265 )     53,244  
Trade accounts payable   114,234       31,353       155,563       (58,313 )
Accrued expenses   3,860       89,671       (150,032 )     159,353  
Other assets and liabilities   (4,017 )     5,286       (20,593 )     298  
Net cash provided by (used in) operating activities $ 27,246     $ 33,691     $ (66,838 )   $ 48,383  
Investing activities:                              
Purchases of property and equipment $ (20,043 )   $ (17,899 )   $ (65,602 )   $ (56,693 )
Acquisitions of businesses, net of cash acquired   (17,225 )     (37,044 )     (59,755 )     (62,508 )
Other   360       296       900       1,790  
Net cash used in investing activities $ (36,908 )   $ (54,647 )   $ (124,457 )   $ (117,411 )
Financing activities:                              
Long-term debt borrowings $     $     $ 2,566,000     $  
Long-term debt repayments   (13,663 )     (7,536 )     (3,384,633 )     (22,857 )
Proceeds from issuance of common stock on initial public offering, net               656,485        
Proceeds from issuance of tangible equity units, net               389,000        
Borrowings of the Revolving Credit Facility, net   41,300       31,650       46,400       98,250  
Payment of debt issuance costs               (43,188 )      
Repurchase of shares of common stock         (325 )     (650 )     (325 )
Shares issued under share-based compensation plan, including
tax effects
  127       453       531       598  
Payment of acquisition earn-outs   (1,500 )           (4,156 )      
Purchase of redeemable noncontrolling interest   (2,016 )           (2,316 )      
Payment of financing lease obligations   (3,640 )     (2,901 )     (9,276 )     (8,625 )
Net cash provided by financing activities $ 20,608     $ 21,341     $ 214,197     $ 67,041  
Net increase (decrease) in cash and cash equivalents   10,946       385       22,902       (1,987 )
Cash and cash equivalents at beginning of year   25,027       11,256       13,071       13,628  
Cash and cash equivalents at end of year $ 35,973     $ 11,641     $ 35,973     $ 11,641  
                               

BrightSpring Health Services, Inc. and Subsidiaries
Reconciliation of EBITDA and Adjusted EBITDA
For the three and nine months ended September 30, 2024 and 2023
(Unaudited)

The following table reconciles net loss to EBITDA and Adjusted EBITDA:

($ in thousands) For the Three Months Ended     For the Nine Months Ended  
  September 30,     September 30,  
  2024     2023     2024     2023  
Net loss $ (8,981 )   $ (130,124 )   $ (35,925 )   $ (149,634 )
Income tax expense (benefit)   9,760       (5,807 )     (23,000 )     (12,987 )
Interest expense, net   56,061       83,678       173,520       241,539  
Depreciation and amortization   50,608       50,774       149,601       151,324  
EBITDA $ 107,448     $ (1,479 )   $ 264,196     $ 230,242  
Non-cash share-based compensation (1)   15,210       825       55,194       2,100  
Acquisition, integration, and transaction-related costs (2)   11,767       6,319       25,331       13,754  
Restructuring and divestiture-related and other costs (3)   6,672       4,527       28,065       16,172  
Legal costs and settlements (4)   8,920       117,042       21,886       121,706  
Significant projects (5)   1,000       1,935       2,604       6,899  
Management fee (6)         1,383       23,381       4,248  
Unreimbursed COVID-19 related costs         (48 )           88  
Total adjustments $ 43,569     $ 131,983     $ 156,461     $ 164,967  
Adjusted EBITDA $ 151,017     $ 130,504     $ 420,657     $ 395,209  
(1) Represents non-cash share-based compensation to certain members of our management and full-time employees. The three and nine months ended September 30, 2024 includes $14.4 million and $35.8 million of costs, respectively, related to new equity awards granted upon the completion of our IPO under the 2024 Equity Incentive Plan. The nine months ended September 30, 2024 includes $15.0 million of previously unrecognized share-based compensation expense related to performance-vesting options under the 2017 Stock Plan, a portion of which vested upon completion of the IPO.
   
(2) Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions. The three months ended September 30, 2024 includes acquisition and integration related costs of $7.5 million, earn-out adjustments from previous acquisitions of $0.9 million, and other non-routine transaction costs of $2.9 million, as compared to acquisition and integration related costs of $3.7 million and other non-routine transaction costs of $0.9 million for the three months ended September 30, 2023. These costs also included $0.5 million and $6.0 million of costs related to the IPO Offerings which were not capitalizable for the three and nine months ended September 30, 2024, respectively, compared to $1.7 million and $1.9 million for the three and nine months ended September 30, 2023, respectively.
   
(3) Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures. These costs included $12.7 million of unamortized debt issuance costs associated with the extinguishment of our Second Lien Facility in the nine months ended September 30, 2024. These costs also included $1.8 million and $3.7 million of intangible asset and other non-cash investment impairment for the three and nine months ended September 30, 2024, respectively, as compared to $1.4 million and $7.4 million for the three and nine months ended September 30, 2023, respectively.
   
(4) Represents settlement and defense costs associated with certain historical PharMerica litigation matters, including the Silver matter, all of which are expected to be completed in 2024. See Note 10 within the unaudited condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q for additional information.
   
(5) Represents costs associated with certain transformational projects and for the periods presented primarily included general ledger system implementation and pharmacy billing system implementation, which both completed in the second fiscal quarter of 2024; and ransomware attack response costs. Ransomware attack response costs were $1.0 million for the three and nine months ended September 30, 2024, compared to $0.6 million and $3.1 million for the three and nine months ended September 30, 2023, respectively.
   
(6) Represents annual management fees payable to the Managers under the Monitoring Agreement through the date of the IPO, and $22.7 million of termination fees resulting from the Monitoring Agreement being terminated upon completion of the IPO Offerings. All management fees have ceased following the completion of the IPO.
   

BrightSpring Health Services, Inc. and Subsidiaries
Reconciliation of Adjusted EPS
For the three and nine months ended September 30, 2024 and 2023
(Unaudited)

The following table reconciles diluted EPS to Adjusted EPS:

(shares in thousands) For the Three Months Ended     For the Nine Months Ended  
  September 30,     September 30,  
  2024     2023     2024     2023  
Diluted EPS $ (0.04 )   $ (1.11 )   $ (0.18 )   $ (1.26 )
Non-cash share-based compensation (1)   0.07       0.01       0.28       0.02  
Acquisition, integration, and transaction-related costs (1)   0.06       0.05       0.13       0.11  
Restructuring and divestiture-related and other costs (1)   0.03       0.04       0.14       0.13  
Legal costs and settlements (1)   0.04       0.93       0.11       0.96  
Significant projects (1)         0.02       0.01       0.05  
Management fee (1)         0.01       0.12       0.03  
Unreimbursed COVID-19 related costs (1)                      
Income tax impact on adjustments (2)(3)   (0.05 )     (0.03 )     (0.27 )     (0.10 )
Adjusted EPS $ 0.11     $ (0.08 )   $ 0.34     $ (0.06 )
                               
Weighted average common shares outstanding used in calculating diluted U.S. GAAP net loss per share   198,491       117,864       190,541       117,871  
Weighted average common shares outstanding used in calculating diluted Non-GAAP earnings (loss) per share   208,694       126,346       199,930       126,428  
(1) This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA.
   
(2) The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non-GAAP adjustment.
   
(3) For the nine months ended September 30, 2024, the income tax impact on adjustments is inclusive of a discrete tax benefit related to the Silver matter that was finalized in connection with the signing of the settlement agreement during the second fiscal quarter of 2024.
   


Primary Logo

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Trump Loses $1.9B In Net Worth As DJT Stock Tumbles 2nd Time This Week

Former President Donald Trump has seen a significant decline in his net worth, losing approximately $1.9 billion due to a steep drop in Trump Media & Technology Group Corp DJT stock.

What Happened: According to Benzinga Pro, DJT shares fell by 11.72%, closing at $35.34 on Thursday. This followed a 22% decline on Wednesday after the stock had reached an intraday high of $54.68 on Tuesday. The reasons for the two-day sell-off remain unclear, but the stock has attracted the attention of speculators and shortsellers.

S3 Partners, a research group, indicated that the surge in DJT shares during October might have been driven by short sellers covering their positions, resulting in a short squeeze. They noted the stock’s high squeeze risk due to limited float and significant short interest, which is closely linked to Trump’s election prospects, CBS News reported on Thursday.

See Also: Trump’s Billionaire Ally Plans To Join Elon Musk’s DOGE If Named Treasury Secretary, Recommends Elimination Of These Subsidies

Trump, the largest shareholder with around 115 million shares in Trump Media, saw his stake’s value drop from nearly $6.3 billion at Tuesday’s peak to about $4 billion based on Thursday’s closing price.

Trump Media and his company are yet to respond to Benzinga’s queries.

Why It Matters: The volatility in DJT stock is not new, as it has been highly unpredictable since going public following a SPAC merger. The stock’s movements are closely tied to Trump’s 2024 election prospects, with potential outcomes significantly impacting its value. According to a report from S3 Partners, a Trump victory could push the stock to $60, while a loss might render shares “worthless.”

Earlier this week, DJT stock experienced multiple volatility halts as prices fluctuated significantly. The stock was halted several times on Tuesday, reflecting its unpredictable nature and the market’s sensitivity to political developments.

Read Next:

Image via Shutterstock

This story was generated using Benzinga Neuro and edited by Pooja Rajkumari

Market News and Data brought to you by Benzinga APIs

Biodesix Announces Third Quarter 2024 Results and Highlights

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million;

Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023;

Q3 2024 Net loss improved by 6% compared to Q3 2023;

Conference Call and Webcast Today at 8:30 a.m. ET

LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) — Biodesix, Inc. BDSX, a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024.

“The Biodesix team is pleased to report another solid quarter focused on executing and delivering on our three main goals – driving revenue growth through the adoption of our lung diagnostic tests and biopharma services, continued implementation of operational efficiencies, and maintaining a cost-disciplined approach as we drive our business to profitability,” said Scott Hutton, CEO of Biodesix.

“We reported 40% year-over-year growth in lung diagnostics revenue, a growing book of biopharma services contracts, sustained gross margins in the high 70% range, and improved Net Loss on our path to profitability. In addition, at the annual meeting of the American College of Chest Physicians (CHEST), we presented new clinical data on our Nodify XL2® and Nodify CDT® tests, and announced a new clinical study (CLARIFY) to expand our data in diverse patient populations tested in a real-world clinical setting. Building on this momentum, we are reiterating our prior guidance of $70-$72 million for 2024 and we look forward to achieving Adjusted EBITDA profitability in the second half of 2025. At Biodesix, our tests play a vital role in treating the deadliest of all cancers. Our committed and driven team embraces the opportunity, and the responsibility, to transform the standard of care to improve outcomes for patients.”

Third Quarter Ended September 30, 2024 Business Highlights

  • Grew Lung Diagnostic test volume to 13,900, a 34% improvement over the third quarter of 2023.
  • Quarterly gross profit margin of 77.0% versus 76.1% for the third quarter of 2023.
  • Presented compelling new data at the CHEST Annual Meeting and announced the launch of a new clinical study, CLARIFY.
    • New data was presented detailing the experience of healthcare providers using the Nodify Lung® Nodule Risk Assessment Tests (Nodify XL2 and Nodify CDT tests) in over 35,000 patients tested in a real-world clinical setting. Results shared were consistent with prior studies, highlighting the high proportion of results that up- or down-classify patients into actionable risk categories with clear, guideline-recommended, diagnostic plans.
    • The new study, CLARIFY, is designed to confirm performance of the Nodify CDT and Nodify XL2 tests in diverse patient subgroups through a retrospective chart review of up to 4,000 patients that were tested in a real-world clinical setting. The study’s intent is to expand the extensive evidence characterizing the validation and utility of Nodify Lung testing.

Third Quarter Ended September 30, 2024 Financial Highlights

  • Total revenue of $18.2 million, an increase of 35% over the third quarter 2023:
    • Lung Diagnostic revenue of $17.2 million reflected a year-over-year increase of 40% driven by the continued adoption of Nodify XL2 and Nodify CDT nodule risk assessment tests and strong reimbursement. However, test volumes were impacted at the end of the third quarter by disruption to patients, healthcare providers, and Biodesix teammates in the southeast due to Hurricane Helene;
    • Biopharmaceutical Services revenue of $1.0 million decreased 17% year-over-year, driven by the timing of receipt of samples and shift of the completion of certain projects from the end of the third quarter into the beginning of the fourth;
  • Third quarter 2024 gross profit of $14.0 million, or 77.0% gross margin compared to 76.1% gross margin in the comparable prior year period. Our steady margin performance is primarily driven by volume growth in Lung Diagnostic testing that continues to drive down the per test costs;
  • Operating expenses (excluding direct costs and expenses) of $22.6 million, an increase of 29% as compared to the third quarter 2023, which includes $3.0 million of non-cash stock compensation expense and depreciation and amortization as compared to $1.7 million in third quarter of 2023. This increase is primarily attributable to an increase in sales and marketing costs to support both business lines’ sales growth to enhance product awareness and drive adoption, and an increase in depreciation expense related to the leasehold improvements in the Company’s Louisville, CO offices and laboratory which opened in January 2024;
  • Net loss of $10.3 million, an improvement of 6% as compared to the same period of 2023;
  • Adjusted EBITDA was a loss of $5.6 million, a slight increase over the loss of $5.4 million in the third quarter of 2023 and consistent with the second quarter of 2024;
  • Cash and cash equivalents of $31.4 million as of September 30, 2024, a decrease from $42.2 million from June 30, 2024;
    • Cash and cash equivalents as of September 30, 2024 includes the final milestone payment of $6.1 million for the acquisition of Integrated Diagnostics in 2018.

2024 – 2025 Financial Outlook

The Company is reiterating the 2024 revenue forecast of between $70 million and $72 million.

Conference call and webcast information

Listeners can register for the webcast via this link. Analysts who wish to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Company’s investor relations page on the website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.

For a full list of Biodesix press releases and webinars, please visit biodesix.com.

About Biodesix

Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information about Biodesix, visit biodesix.com.

Trademarks: Biodesix, Nodify Lung, Nodify XL2, Nodify CDT, IQLung, GeneStrat, GeneStrat NGS, and VeriStrat are trademarks or registered trademarks of Biodesix, Inc. The ddPCR technology is a trademark of Bio-Rad Laboratories, Inc.

Use of Non-GAAP Financial Measure

Biodesix reported results are presented in accordance with generally accepted accounting principles in the United States (GAAP). Biodesix has provided in this press release financial information that has not been prepared in accordance with GAAP. Biodesix uses the non-GAAP financial measure, Adjusted EBITDA, internally in analyzing its financial results and believes that use of this non-GAAP financial measure is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing Biodesix financial results with other companies in its industry, many of which present similar non-GAAP financial measures. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with Biodesix financial statements prepared in accordance with GAAP. A reconciliation of Biodesix historical non-GAAP financial measure to the most directly comparable GAAP measure has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation.

Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it provides a comparable overview of our operations across historical periods. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of Net loss to Adjusted EBITDA, helps investors make comparisons between our Company and other companies that may have different capital structures, different tax rates, and/or different forms of employee compensation.

Adjusted EBITDA is used by our management team as an additional measure of our performance for purposes of business decision-making, including managing expenditures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our financial results that may not be shown solely by period- to-period comparisons of Net loss or Loss from operations. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items and may not be directly comparable to similarly titled metrics used by other companies.

We calculate Adjusted EBITDA as Net loss adjusted to exclude interest, income tax expense, if any, depreciation and amortization, share-based compensation expense, loss on debt extinguishments, net, COVID-19 revenue, COVID-19 direct costs and expenses, change in fair value of warrant liabilities, net, other income, net, and other non-recurring items. Non-recurring items are excluded as they are not representative of our underlying operating performance. We also exclude revenue and direct costs and expenses associated with COVID-19 because we believe that these revenues and expenses do not reflect expected future operating results as they do not represent our Lung Diagnostic and Biopharmaceutical Services business. Adjusted EBITDA should be viewed as a measure of operating performance that is a supplement to, and not a substitute for Loss from operations, Net loss, and other GAAP measures.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, expectations regarding revenue and margin growth and its impact on profitability, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company’s ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024 or subsequent quarterly reports on Form 10-Q during 2024, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contacts:
Media:
Natalie St. Denis
natalie.stdenis@
biodesix.com
(720) 925-9285

Investors:
Chris Brinzey
chris.brinzey@
westwicke.com
(339) 970-2843

Biodesix, Inc.
Condensed Balance Sheets (unaudited)
(in thousands, except share data)
       
    September 30, 2024     December 31, 2023  
Assets  
Current assets            
Cash and cash equivalents   $ 31,406     $ 26,284  
Accounts receivable, net of allowance for credit losses of $246 and $65     8,036       7,679  
Other current assets     4,575       5,720  
Total current assets     44,017       39,683  
Non-current assets            
Property and equipment, net     28,683       27,867  
Intangible assets, net     6,438       7,911  
Operating lease right-of-use assets     1,918       1,745  
Goodwill     15,031       15,031  
Other long-term assets     6,656       6,859  
Total non-current assets     58,726       59,413  
Total assets   $ 102,743     $ 99,096  
             
Liabilities and Stockholders’ Equity  
Current liabilities            
Accounts payable   $ 2,537     $ 2,929  
Accrued liabilities     8,553       7,710  
Deferred revenue     676       324  
Current portion of operating lease liabilities     624       252  
Current portion of contingent consideration           21,857  
Current portion of notes payable     29       51  
Other current liabilities     544       293  
Total current liabilities     12,963       33,416  
Non-current liabilities            
Long-term notes payable, net of current portion     36,112       35,225  
Long-term operating lease liabilities     25,191       25,163  
Other long-term liabilities     620       712  
Total non-current liabilities     61,923       61,100  
Total liabilities     74,886       94,516  
Commitments and contingencies            
Stockholders’ equity            
Preferred stock, $0.001 par value, 5,000,000 authorized;
0 (2024 and 2023) issued and outstanding
           
Common stock, $0.001 par value, 200,000,000 authorized;
145,465,941 (2024) and 96,235,883 (2023) shares issued and outstanding
    145       96  
Additional paid-in capital     481,958       424,050  
Accumulated deficit     (454,246 )     (419,566 )
Total stockholders’ equity     27,857       4,580  
Total liabilities and stockholders’ equity   $ 102,743     $ 99,096  
Biodesix, Inc.
Condensed Statements of Operations (unaudited)
(in thousands, except per share data)
 
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2024     2023     2024     2023  
Revenues                        
Diagnostic Testing revenue   $ 17,168     $ 12,301     $ 47,503     $ 32,395  
Biopharmaceutical Services and other revenue     983       1,190       3,391       2,024  
Total revenues     18,151       13,491       50,894       34,419  
Direct costs and expenses     4,179       3,229       11,231       9,636  
Research and development     2,547       1,938       7,145       8,099  
Sales, marketing, general and administrative     20,016       15,496       60,232       51,136  
Impairment loss on intangible assets                 135       20  
Total operating expenses     26,742       20,663       78,743       68,891  
Loss from operations     (8,591 )     (7,172 )     (27,849 )     (34,472 )
Other (expense) income:                        
Interest expense     (2,041 )     (2,386 )     (6,506 )     (7,207 )
Loss on extinguishment of liabilities                 (248 )      
Change in fair value of warrant liability, net           (1,393 )           (1,332 )
Other (expense) income, net     374       2       (77 )     4  
Total other expense     (1,667 )     (3,777 )     (6,831 )     (8,535 )
                         
                         
Net loss   $ (10,258 )   $ (10,949 )   $ (34,680 )   $ (43,007 )
Net loss per share, basic and diluted   $ (0.07 )   $ (0.14 )   $ (0.28 )   $ (0.55 )
Weighted-average shares outstanding, basic and diluted     146,296       79,709       123,634       78,672  
Biodesix, Inc.
Reconciliation of Net Loss to Adjusted EBITDA (unaudited)
(in thousands)
 
  Three Months Ended September 30,     Nine Months Ended September 30,  
  2024     2023     2024     2023  
Net loss $ (10,258 )   $ (10,949 )   $ (34,680 )   $ (43,007 )
Interest expense   2,041       2,386       6,506       7,207  
Depreciation and amortization   1,492       782       4,324       2,351  
Share-based compensation expense   1,515       954       5,373       4,292  
Loss on extinguishment of liabilities               248        
COVID-19 Revenue                     (13 )
COVID-19 Direct costs and expenses                     1  
Change in fair value of warrant liability, net         1,393             1,332  
Other expense (income), net   (374 )     (2 )     77       (4 )
Adjusted EBITDA $ (5,584 )   $ (5,436 )   $ (18,152 )   $ (27,841 )


Primary Logo

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Jim Cramer Warns Apple Stock Should Have 'Never Been Up That Much' After Q3 Earnings Even As This Analyst Defends iPhone 16 Launch

After Apple Inc.’s AAPL forecast cuts following the company’s fourth-quarter results, “Mad Money” host Jim Cramer cautions that “the stock should never have been up that much,” while Dan Ives defends the company’s strong iPhone 16 launch.

What Happened: On Thursday, Cramer took to X, formerly Twitter, and suggested that Apple’s lowered financial forecast, indicating a slowdown, has now been “absorbed” by the market, which he thinks brings down overhyped expectations to a more “reasonable” level

Cramer also implied Apple hasn’t faced as much criticism for spending on AI compared to other tech giants, possibly because investors don’t think Apple’s AI efforts are as significant or game-changing.

See Also: The Guy Who Tracked Elon Musk, Taylor Swift’s Private Jet Wants To Know ‘Who’s Behind’ His Suspended Social Media Accounts

“Oh and, tell me, please, who was surprised by the forecast guidedown? The stock should never have been up that much…,” he stated.

Contrarily, Wedbush analyst Ives defended Apple’s fourth-quarter performance. He lauded the successful launch of iPhone 16 and forecasted a robust December quarter for the company, propelled by the rollout of Apple Intelligence.

Ives also conveyed his conviction that the strong performance will persist throughout the rest of the fiscal year 2025, despite a lower guide delta for wearables, Mac, and iPad.

Why It Matters: Apple announced fiscal fourth-quarter revenue of $94.9 billion, surpassing analyst predictions of $94.56 billion. The company also reported adjusted earnings of $1.64 per share for the quarter, exceeding expectations of $1.60 per share.

This marks the seventh consecutive quarter that Apple has exceeded analyst forecasts for both revenue and earnings,  according to Benzinga Pro.

During the earnings call on Thursday, Apple CEO Tim Cook said that the adoption rate of iOS 18.1 has doubled that of its predecessor, iOS 17.1, indicating a strong demand for the new iPhone 16.

However, previously it was reported that Apple had to resort to aggressive pricing strategies, including discounts on Alibaba’s Tmall, to counter the initial lukewarm response to the iPhone 16 in China.

Price Action: Apple’s stock fell 1.8% on Thursday to close at $225.91, and fell over 1.2% in premarket trading on Friday. Year-to-date, Apple’s shares are up 21.7%, according to Benzinga Pro data.

Read Next:

Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Photo courtesy: Apple

Market News and Data brought to you by Benzinga APIs